Highlights From TED360 Forum: Differential Diagnosis, Pathogenesis, and Medical Treatment Trends

Highlights From TED360 Forum: Differential Diagnosis, Pathogenesis, and Medical Treatment Trends is organized by Healio, Vindico Medical Education.,,This enduring material is approved for 1 year from the date of original release, June 30, 2022, to June 29, 2023.,,Activity Description:,Thyroid eye disease (TED) is a multifactorial, autoimmune disorder with a wide spectrum of signs and symptoms. It is frequently misdiagnosed, due to both the heterogeneous clinical presentation and a failure to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at increased risk for complications; however, a differential diagnosis can be achieved with the assistance of imaging, and early diagnosis and treatment may limit disfigurement and reduce vision loss. Ophthalmologists, oculoplastic surgeons, ophthalmic plastic and reconstructive surgeons, neuro-ophthalmologists, and endocrinologists should be knowledgeable about the conventional and new therapies available for the treatment of patients with TED and how to apply this information into practice. While new information on TED continues to be published and presented, there is a need for education that addresses the gamut of its management.,This first of two TED360 Forum eMonographs aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with TED. In this eMonograph, expert faculty review the differential diagnosis, pathogenesis, and medical treatment trends in TED management. In addition, case challenges will demonstrate the application of the presented material into practice.,The intended audience for this activity is oculoplastic surgeons, ophthalmic plastic and reconstructive surgeons, neuro-ophthalmologists, endocrinologists, ophthalmologists, and other health care professionals involved in the management of patients with TED.,,Learning Objectives:,Upon successful completion of this activity, participants should be better able to:,• Review the etiology, pathogenesis, and risk factors for TED to better understand why early diagnosis can improve outcomes in patients.,• Examine current guidelines and best practices that can improve the diagnosis of TED so that early treatment can be initiated.,• Assess the safety and efficacy of current medical treatments that can improve the management of patients with TED.,• Evaluate the benefit/risk profile of insulin-like growth factor 1 receptor (IGF-1R) therapy and how it may be incorporated into practice, safely and effectively.,• Examine case presentations, clinical findings, and management solutions that may improve overall outcomes for patients with TED.